source
- Biogen signs $411 million deal with TrimTech to develop protein degraders for neurodegenerative diseasesBiogen announced a collaboration with UK‑based TrimTech Therapeutics, valued at up to $411 million in biobucks, to create small‑molecule protein degraders aimed at neurodegenerative disorders. The…
- Eli Lilly makes 14th acquisition of 2026, buying a blood-cancer biotechEli Lilly announced it has acquired a blood‑cancer focused biotechnology company, marking its 14th acquisition in 2026. The deal reflects Lilly’s aggressive expansion strategy, funded by strong sa…